证券代码：688065 证券简称：凯赛生物 公告编号：2025-009 二、董事会会议审议情况 审议通过《关于审议<市值管理制度>的议案》 为加强公司市值管理，切实推动公司投资价值提升，增强投资者回报，维护投 资者利益，根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司 信息披露管理办法》《上市公司监管指引第 10 号——市值管理》等法律法规、规范 性文件和《公司章程》等规定，公司编制了《上海凯赛生物技术股份有限公司市值 管理制度》。 上海凯赛生物技术股份有限公司 表决结果：同意 7 票，反对 0 票，弃权 0 票。 第二届董事会第二十八次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 特此公告。 上海凯赛生物技术股份有限公司（以下简称"公司"）于 2025 年 3 月 24 日在 公司会议室召开第二届董事会第二十八次会议。本次董事会会议通知已于 2025 年 3 月 21 日以电子邮件、电话方式送达给全体董事。本次会议由董事长 Xiucai Liu（刘 修才）主持，会议以 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-008 上海凯赛生物技术股份有限公司 关于上海曜修生物技术合伙企业（有限合伙） 通过协议受让股权及认购新增发行股份事项的进展公告 1 赛生物技术股份有限公司向特定对象发行 A 股股票募集说明书（注册稿）》，正有 序推进发行前各项工作。 公司及上海曜修将积极推进上述工作并严格按照有关法律法规的规定和要求履 行 信 息 披 露 义 务 。 公 司 公 开 披 露 的 信 息 以 上 海 证 券 交 易 所 网 站 （http://www.sse.com.cn）和公司指定媒体刊登的信息为准。敬请广大投资者注 意投资风险。 特此公告。 上海凯赛生物技术股份有限公司 董 事 会 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据相关交易方案，上海曜修生物技术合伙企业（有限合伙）（以下简称"上 海曜修"）获得 Cathay Industrial Biotech Ltd.（以下简称"CIB"）以 116,655,640 股上海凯赛生物技术股份有限公司（以下简称"凯赛生物" ...

Investment Rating - Investment Rating: Buy (Maintain) [2] Core Views - The company is expected to achieve a significant revenue increase in 2024, with projected revenue of 2.956 billion yuan, a year-on-year increase of 39.84%, and a net profit of 487 million yuan, up 32.80% year-on-year [6] - The collaboration with Ningde Times marks a key milestone in commercializing bio-based polyamide materials, enhancing market penetration in the new energy sector [7] - The long-term growth path is clear, supported by technological advantages and policy incentives, particularly in the context of carbon neutrality goals [8] Summary by Sections Financial Performance - In 2024, the company anticipates a total revenue of 2.956 billion yuan, with a profit total of 546 million yuan and a net profit attributable to shareholders of 487 million yuan [5] - The fourth quarter of 2024 is projected to generate revenue of 741 million yuan, a year-on-year increase of 35.12%, and a net profit of 142 million yuan, up 168.91% year-on-year [6] Business Development - The demand for long-chain dicarboxylic acids is recovering, with new product capacity for sebacic acid driving significant growth in production and sales [6] - The establishment of a joint venture with Ningde Times focuses on the development and production of bio-based composite materials, marking a substantial step in the commercialization of these materials [7] Market Outlook - The company is positioned to benefit from structural advantages in synthetic biology technology, with a strong market share in bio-based long-chain dicarboxylic acids [8] - The global implementation of the EU carbon border tax (CBAM) in 2026 is expected to enhance the competitive edge of the company's bio-based materials in export-oriented industries [9] Investment Recommendations - The forecast for net profit attributable to shareholders for 2024-2026 is 473 million, 655 million, and 857 million yuan, respectively, with corresponding growth rates of 29.1%, 38.4%, and 30.8% [10]

Investment Rating - Investment Rating: Buy (Maintain) [2] Core Views - The company is expected to achieve significant revenue growth in 2024, with projected revenue of 2.956 billion yuan, a year-on-year increase of 39.84%, and a net profit of 487 million yuan, up 32.80% year-on-year [6] - The collaboration with Ningde Times marks a key milestone in commercializing bio-based polyamide materials, enhancing market penetration in the new energy sector [7] - The long-term growth path is clear, supported by technological advantages and policy incentives, particularly in the context of carbon neutrality goals [8] Summary by Sections Financial Performance - In 2024, the company anticipates a total revenue of 2.956 billion yuan and a net profit of 487 million yuan, with a basic earnings per share of 0.84 yuan [5][6] - The fourth quarter of 2024 is projected to generate revenue of 741 million yuan, a year-on-year increase of 35.12%, and a net profit of 142 million yuan, up 168.91% year-on-year [6] Business Development - The demand for long-chain dicarboxylic acids is recovering, and the new product, dodecanedioic acid, is expected to drive significant growth in production and sales [6] - The establishment of a joint venture with Ningde Times focuses on the development and production of bio-based composite materials, marking a significant step in the commercialization of these materials [7] Market Outlook - The company is positioned to benefit from the increasing penetration of new energy vehicles and the growing demand for bio-based materials in various sectors [8] - The global implementation of carbon tariffs and the inclusion of bio-based polyamide in strategic material lists in China are expected to enhance the company's competitive advantage [9]

根据《上市公司股份回购规则》《上海证券交易所上市公司自律监管指引第 7 号——回购股份》等相关规定，现将公司回购股份情况公告如下： 证券代码：688065 证券简称：凯赛生物 公告编号：2025-007 上海凯赛生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至 2025 年 2 月 28 日，上海凯赛生物技术股份有限公司（以下简称"公 司"）通过上海证券交易所交易系统以集中竞价交易方式回购公司股份 220,946 股,占公司总股本 583,378,039 股的比例为 0.0379%。回购成交的最高价为 45.95 元/股，最低价为 44.08 元/股，支付的资金总额为人民币 9,995,695.95 元（不含 印花税、交易佣金等交易费用)。 一、回购股份的基本信息 2024 年 10 月 21 日，公司召开第二届第二十四次董事会会议，审议通过了 《关于以集中竞价交易方式回购公司股份的方案》，同意公司使用自有资金或自 筹资金以集中竞价交易 ...

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company's long-chain dicarboxylic acid business is continuously recovering, and significant progress has been made in promoting the application of bio-based polyamide composites [1][8] - The company reported a substantial year-on-year revenue growth of 40% for 2024, driven by the recovery in demand for long-chain dicarboxylic acids, particularly the new product, decanedioic acid [8] - The company is actively expanding its bio-based materials ecosystem in collaboration with industry chain clients, with notable advancements in the promotion of bio-based polyamide composite materials [8] Financial Data and Profit Forecast - Total revenue for 2023 is projected at 2,114 million, with a year-on-year decrease of 13.4%, while 2024 revenue is expected to rise to 2,956 million, reflecting a growth rate of 39.8% [7] - The net profit attributable to the parent company for 2024 is forecasted at 487 million, representing a year-on-year increase of 32.9% [7] - The company anticipates a significant increase in net profit to 698 million in 2025, with a projected growth rate of 43.3% [7][8]

Financial Performance - In 2024, the company achieved operating revenue of CNY 295,648.59 million, a year-on-year increase of 39.84%[4] - The total profit for 2024 was CNY 54,573.76 million, reflecting a year-on-year growth of 21.57%[4] - The net profit attributable to shareholders was CNY 48,673.00 million, up 32.80% compared to the previous year[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 50.87% to CNY 46,249.85 million[4] - Basic earnings per share rose to CNY 0.84, representing a 33.33% increase year-on-year[4] - The weighted average return on equity was 4.33%, an increase of 1.02 percentage points from the previous year[4] Assets and Equity - Total assets at the end of 2024 were CNY 1,901,648.11 million, a 0.97% increase from the beginning of the year[4] - The equity attributable to shareholders reached CNY 1,150,470.11 million, up 3.05% from the start of the year[4] Market Expansion and R&D - The company successfully expanded into the long-chain dicarboxylic acid market, significantly increasing sales volume and revenue[5] - The company continued to invest in R&D for bio-based new materials, achieving progress in cooperation with leading enterprises in downstream sectors[4]

Group 1 - The establishment of a new company,招商凯赛新材料 (Anhui) Partnership, with a registered capital of 650 million yuan [1] - The business scope includes new material technology promotion services and investment activities using its own funds [1] - The company is co-funded by曜酰生物技术 (Shanghai) Partnership, which is jointly held by凯赛生物 and others [1]

证券代码：688065 证券简称：凯赛生物 公告编号：2025-005 上海凯赛生物技术股份有限公司 关于上海曜修生物技术合伙企业（有限合伙） 通过协议受让股权及认购新增发行股份事项的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 根据相关交易方案，上海曜修生物技术合伙企业（有限合伙）（以下简称"上 海曜修"）获得 Cathay Industrial Biotech Ltd.（以下简称"CIB"）以 116,655,640 股上海凯赛生物技术股份有限公司（以下简称"凯赛生物"、"公司" 或"上市公司"）股份以作为 CIB 对上海曜修的出资款，并以现金方式认购上市公 司不超过 153,595,531 股（含本数）的股份，完成本次收购交易事宜。 上述交易的具体内容详见公司分别于 2023 年 6 月 26 日披露的《收购报告书摘 要》和其他相关公告、2023 年 8 月 18 日披露的《收购报告书摘要（修订稿）》和 其他相关公告、2024 年 12 月 17 日披露的《关于控股股东签署<股票出资协议之补 充协议暨股份 ...

证券代码：688065 证券简称：凯赛生物 公告编号：2025-004 上海凯赛生物技术股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 截至 2025 年 1 月 31 日，上海凯赛生物技术股份有限公司（以下简称"公 司"）通过上海证券交易所交易系统以集中竞价交易方式回购公司股份 220,946 股,占公司总股本 583,378,039 股的比例为 0.0379%。回购成交的最高价为 45.95 元/股，最低价为 44.08 元/股，支付的资金总额为人民币 9,995,695.95 元（不含 印花税、交易佣金等交易费用)。 截至 2025 年 1 月 31 日，公司通过上海证券交易所交易系统以集中竞价交易 方式回购公司股份 220,946 股,占公司总股本 583,378,039 股的比例为 0.0379%。 回购成交的最高价为 45.95 元/股，最低价为 44.08 元/股，支付的资金总额为人 民币 9,995,695.95 元（不含印花税、交 ...